Neurologic Deficits and Recovery in Chronic Subdural Hematoma

Sponsor
University of New Mexico (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05900557
Collaborator
(none)
160
1
71

Study Details

Study Description

Brief Summary

Chronic subdural hematoma (cSDH) is one of the most common problems treated by neurosurgeons, particularly as the population ages. While often dismissed as a benign problem, it has become clear that cSDH is associated with worse long term functional and cognitive outcomes compared to matched controls. Though surgical techniques for treatment of cSDH are becoming more effective and safe, a persisting problem of fluctuating, stroke-like neurological deficits has re-emerged. Such deficits are not always directly related to hematoma mass effect and not always relieved with surgical decompression, but can result in prolonged hospital course, additional workup, and sometimes even additional invasive treatments. While the cause of such events is unknown, we recently documented for the first time that massive waves of spreading depolarization can occur in these patients and were closely linked to such neurologic deficits in some patients. In the current study, we plan to expand on these preliminary findings with rigorous, standardized application of post operative subdural electrocorticography monitoring, pioneered at our institution to detect SD. We also plan to build on our large retrospective analysis estimating the overall incidence of such deficits in cSDH patients by assessing multiple proposed risk factors for SD. In addition, for the first time, we will assess the short- and long-term consequences of cSDH and SD with detailed functional, cognitive, and headache related outcome measurement. These assessments are based on several remarkable cases we have observed with time-locked neurologic deterioration associated with recurrent SD. This study qualifies as a mechanistic clinical trial in that we will be prospectively assigning patients to the intervention of SD monitoring and assessing outcomes related to the occurrence of SD. This constitutes the application of a novel measure of brain signaling and assessing biomarkers of these physiologic processes of SD. These studies will provide critically needed information on this novel mechanism for neurologic deficits and worse outcomes after cSDH evacuation. Upon successful completion, we would identify a targetable mechanism for poor outcomes that occur commonly in patients with cSDH. This overall strategy offers the opportunity to radically improve the care of patients with cSDH by focusing on clinical trials of pharmacologic therapies for neurologic deficits in patients with cSDH.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: ECoG monitoring
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Single arm study performing subdural ECoG monitoring to assess for presence or absence of spreading depolarization.Single arm study performing subdural ECoG monitoring to assess for presence or absence of spreading depolarization.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
Dec 1, 2028
Anticipated Study Completion Date :
Dec 1, 2029

Arms and Interventions

Arm Intervention/Treatment
Experimental: ECoG monitoring

Patients undergoing standard of care surgical evacuation of cSDH. will have subdural ECoG monitoring electrode placed crossing frontal and temporal lobes for 1-5 days of post operative monitoring. All subjects will undergo long term followup testing.

Diagnostic Test: ECoG monitoring
Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.

Outcome Measures

Primary Outcome Measures

  1. Post operative neurologic deterioration. [1-5 days]

    Incidence of decline in Markwalder grading scale (0[normal]-4[comatose]) or Glasgow coma scale (3[no response] to 15[normal]) by one point.

Secondary Outcome Measures

  1. eGOS [30day, 90 day, 180 day]

    Extended Glasgow outcome scale 1(dead)- 8(upper good recovery)

  2. MoCA [30day, 90 day, 180 day]

    Montreal Cognitive Assessment (1-30) 30 is the best

  3. NIH toolbox cognitive battery [30day, 90 day, 180 day]

    The NIH Toolbox Cognitive Battery provides an overall summary score along with fluid and crystallized cognition summary scores.

  4. PROMIS 29 profile [30day, 90 day, 180 day]

    The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain

  5. TBI QOL [30day, 90 day, 180 day]

    The TBI-QOL consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life

  6. Headache disability Index [30day, 90 day, 180 day]

    The Headache Disability Index (HDI) is a 27-item questionnaire.The first two questions asks the patient to identify the frequency (1 per month; more than 1 but less than 4 per month; more than 1 per week) and intensity (mild, moderate, severe) of their headache. The remaining questions evaluate quality of life issues to determine headache disability.

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • chronic/ subacute subdural hematoma deemed necessary for surgical evacuation,

  • Ability to consent or have LAR consent

Exclusion Criteria:
  • emergent need for evacuation,

  • acute traumatic subdural hematoma, and

  • severe baseline disability (mRS>2) (modified Rankin Scale)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of New Mexico

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of New Mexico
ClinicalTrials.gov Identifier:
NCT05900557
Other Study ID Numbers:
  • 1454683
First Posted:
Jun 12, 2023
Last Update Posted:
Jun 12, 2023
Last Verified:
May 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 12, 2023